AI Insight
Researchers have identified a protein called NFIL3 that causes CAR T-cells to become exhausted and lose their ability to fight cancer over time. In animal studies, when NFIL3 was disabled in these engineered immune cells, they maintained their cancer-fighting capabilities for longer periods and showed improved tumor control. This discovery suggests that NFIL3 may be a key limiting factor in the long-term effectiveness of CAR T-cell therapy.
Why it matters
This finding could lead to more effective CAR T-cell therapies by providing a specific target to enhance treatment durability. If NFIL3 inhibition proves successful in clinical trials, it may help extend remission periods and improve outcomes for cancer patients receiving this immunotherapy.
A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their cancer-fighting power over time. When NFIL3 was disabled, the cells remained stronger for longer and controlled tumors more effectively in animal models.
Source: A single protein may be holding back CAR T cancer therapy